These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 11971868)
21. Mixture classification model based on clinical markers for breast cancer prognosis. Zeng T; Liu J Artif Intell Med; 2010; 48(2-3):129-37. PubMed ID: 20005686 [TBL] [Abstract][Full Text] [Related]
22. [Prognostic molecular classification of breast cancers based on gene expression profiling]. Feng YM; Li XQ; Sun BC; Gao XC; Gu L; Niu Y; Hao XS Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):900-6. PubMed ID: 17533740 [TBL] [Abstract][Full Text] [Related]
23. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229 [TBL] [Abstract][Full Text] [Related]
24. Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms. Sørlie T; Wang Y; Xiao C; Johnsen H; Naume B; Samaha RR; Børresen-Dale AL BMC Genomics; 2006 May; 7():127. PubMed ID: 16729877 [TBL] [Abstract][Full Text] [Related]
25. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Piccart M; van 't Veer LJ; Poncet C; Lopes Cardozo JMN; Delaloge S; Pierga JY; Vuylsteke P; Brain E; Vrijaldenhoven S; Neijenhuis PA; Causeret S; Smilde TJ; Viale G; Glas AM; Delorenzi M; Sotiriou C; Rubio IT; Kümmel S; Zoppoli G; Thompson AM; Matos E; Zaman K; Hilbers F; Fumagalli D; Ravdin P; Knox S; Tryfonidis K; Peric A; Meulemans B; Bogaerts J; Cardoso F; Rutgers EJT Lancet Oncol; 2021 Apr; 22(4):476-488. PubMed ID: 33721561 [TBL] [Abstract][Full Text] [Related]
26. Tumour heterogeneity revealed by unsupervised decomposition of dynamic contrast-enhanced magnetic resonance imaging is associated with underlying gene expression patterns and poor survival in breast cancer patients. Fan M; Xia P; Liu B; Zhang L; Wang Y; Gao X; Li L Breast Cancer Res; 2019 Oct; 21(1):112. PubMed ID: 31623683 [TBL] [Abstract][Full Text] [Related]
27. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Chang JC; Wooten EC; Tsimelzon A; Hilsenbeck SG; Gutierrez MC; Elledge R; Mohsin S; Osborne CK; Chamness GC; Allred DC; O'Connell P Lancet; 2003 Aug; 362(9381):362-9. PubMed ID: 12907009 [TBL] [Abstract][Full Text] [Related]
28. A systematic overview of chemotherapy effects in breast cancer. Bergh J; Jönsson PE; Glimelius B; Nygren P; Acta Oncol; 2001; 40(2-3):253-81. PubMed ID: 11441936 [TBL] [Abstract][Full Text] [Related]
29. Genomics of adjuvant therapy for breast cancer. Kim SR; Paik S Cancer J; 2011; 17(6):500-4. PubMed ID: 22157294 [TBL] [Abstract][Full Text] [Related]
30. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Pawitan Y; Bjöhle J; Amler L; Borg AL; Egyhazi S; Hall P; Han X; Holmberg L; Huang F; Klaar S; Liu ET; Miller L; Nordgren H; Ploner A; Sandelin K; Shaw PM; Smeds J; Skoog L; Wedrén S; Bergh J Breast Cancer Res; 2005; 7(6):R953-64. PubMed ID: 16280042 [TBL] [Abstract][Full Text] [Related]
31. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097 [TBL] [Abstract][Full Text] [Related]
32. Integrated gene expression profile predicts prognosis of breast cancer patients. Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552 [TBL] [Abstract][Full Text] [Related]
33. Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. Specht K; Harbeck N; Smida J; Annecke K; Reich U; Naehrig J; Langer R; Mages J; Busch R; Kruse E; Klein-Hitpass L; Schmitt M; Kiechle M; Hoefler H Breast Cancer Res Treat; 2009 Nov; 118(1):45-56. PubMed ID: 18925433 [TBL] [Abstract][Full Text] [Related]
34. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986 [TBL] [Abstract][Full Text] [Related]
35. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer. Bertucci F; Finetti P; Viens P; Birnbaum D Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596 [TBL] [Abstract][Full Text] [Related]
36. Gene expression profiling predicts clinical outcome of breast cancer. van 't Veer LJ; Dai H; van de Vijver MJ; He YD; Hart AA; Mao M; Peterse HL; van der Kooy K; Marton MJ; Witteveen AT; Schreiber GJ; Kerkhoven RM; Roberts C; Linsley PS; Bernards R; Friend SH Nature; 2002 Jan; 415(6871):530-6. PubMed ID: 11823860 [TBL] [Abstract][Full Text] [Related]
37. A candidate molecular signature associated with tamoxifen failure in primary breast cancer. Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543 [TBL] [Abstract][Full Text] [Related]
38. Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. Callari M; Cappelletti V; D'Aiuto F; Musella V; Lembo A; Petel F; Karn T; Iwamoto T; Provero P; Daidone MG; Gianni L; Bianchini G Clin Cancer Res; 2016 Jan; 22(2):337-45. PubMed ID: 26423797 [TBL] [Abstract][Full Text] [Related]
39. CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Alfarsi LH; Ansari RE; Craze ML; Toss MS; Masisi B; Ellis IO; Rakha EA; Green AR Breast Cancer Res Treat; 2019 Dec; 178(3):535-544. PubMed ID: 31471836 [TBL] [Abstract][Full Text] [Related]
40. [Gene expression profiling of ER+ breast cancers: to discriminate the poor prognosis tumors or to define the most suitable treatment?]. Chanrion M; Darbon JM Bull Cancer; 2008 May; 95(5):513-8. PubMed ID: 18541515 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]